Citations

Clear

2303 citation(s) found for "Yu, Edward".

Distinct signatures of loss of consciousness in focal impaired awareness versus tonic-clonic seizures
Juan, Elsa , Górska, Urszula , Kozma, Csaba , Papantonatos, Cynthia, Bugnon, Tom , Denis, Colin , Křemen, Václav , Bateman, Lisa M. , Merricks, Edward M. , Blumenfeld, Hal , Tononi, Giulio , Schevon, Catherine A. , Boly, Melanie , Merricks, Edward M , Kremen, Vaclav , Worrell, Gregory A. , Struck, Aaron F.

Mayo Clinic

Brain | November 16, 2022 | Volume: 146 | Issue: 1 | Pages: 109-123

10.1093/brain/awac291 | PMID 36383415 Get It

AbstractLoss of consciousness is a hallmark of many epileptic seizures and carries risks of serious injury and sudden death. While cortical sleep-like activities accompany loss of consciousness during focal impaired awareness seizures, the mechanisms of loss of consciousness during focal to bilateral tonic-clonic seizures remain unclear. Quantifying differences in markers of cortical activation and ictal recruitment between focal impaired awareness and focal to bilateral tonic-clonic seizures may also help us to understand their different consequences for clinical outcomes and to optimize neuromodulation therapies.We quantified clinical signs of loss of consciousness and intracranial EEG activity during 129 focal impaired awareness and 50 focal to bilateral tonic-clonic from 41 patients. We characterized intracranial EEG changes both in the seizure onset zone and in areas remote from the seizure onset zone with a total of 3386 electrodes distributed across brain areas. First, we compared the dynamics of intracranial EEG sleep-like activities: slow-wave activity (1–4 Hz) and beta/delta ratio (a validated marker of cortical activation) during focal impaired awareness versus focal to bilateral tonic-clonic. Second, we quantified differences between focal to bilateral tonic-clonic and focal impaired awareness for a marker validated to detect ictal cross-frequency coupling: phase-locked high gamma (high-gamma phased-locked to low frequencies) and a marker of ictal recruitment: the epileptogenicity index. Third, we assessed changes in intracranial EEG activity preceding and accompanying behavioural generalization onset and their correlation with electromyogram channels. In addition, we analysed human cortical multi-unit activity recorded with Utah arrays during three focal to bilateral tonic-clonic seizures.Compared to focal impaired awareness, focal to bilateral tonic-clonic seizures were characterized by deeper loss of consciousness, even before generalization occurred. Unlike during focal impaired awareness, early loss of consciousness before generalization was accompanied by paradoxical decreases in slow-wave activity and by increases in high-gamma activity in parieto-occipital and temporal cortex. After generalization, when all patients displayed loss of consciousness, stronger increases in slow-wave activity were observed in parieto-occipital cortex, while more widespread increases in cortical activation (beta/delta ratio), ictal cross-frequency coupling (phase-locked high gamma) and ictal recruitment (epileptogenicity index). Behavioural generalization coincided with a whole-brain increase in high-gamma activity, which was especially synchronous in deep sources and could not be explained by EMG. Similarly, multi-unit activity analysis of focal to bilateral tonic-clonic revealed sustained increases in cortical firing rates during and after generalization onset in areas remote from the seizure onset zone.Overall, these results indicate that unlike during focal impaired awareness, the neural signatures of loss of consciousness during focal to bilateral tonic-clonic consist of paradoxical increases in cortical activation and neuronal firing found most consistently in posterior brain regions. These findings suggest differences in the mechanisms of ictal loss of consciousness between focal impaired awareness and focal to bilateral tonic-clonic and may account for the more negative prognostic consequences of focal to bilateral tonic-clonic.
Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers
Casaletto, Kaitlin B. , Kornack, John, VandeBunte, Anna M. , Staffaroni, Adam S., Lee, Shannon, Heuer, Hilary W. , Forsberg, Leah K. , Ramos, Eliana Marisa , Kramer, Joel H. , Yaffe, Kristine , Petrucelli, Leonard , Boxer, Adam L. , Rosen, Howard J. , Apostolova, Liana G. , Barmada, Sami J. , Bordelon, Yvette , Brushaber, Danielle , Coppola, Giovanni, Darby, Ryan, Domoto-Reilly, Kimiko, Faber, Kelley, Fagan, Anne M. , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Gavrilova, Ralitza, Graff-Radford, Jonathon, Graff‐Radford, Neill R. , Grant, Ian , Grossman, Murray, Hall, Matthew , Huey, Edward D. , Kauer, Daniel, Kornak, John , Lago, Argentina Lario , Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diana E., Mackenzie, Ian R. , Masdeux, Joseph C., McGinnis, Scott, Mendez, Mario F. , Mester, Carly , Onyike, Chiadi U. , Pascual, María Belén, Rademakers, Rosa , Rao, Meghana , Rascovsky, Katya, Rankin, Katherine P. , Ritter, Aaron, Savica, Rodolfo , Syrjanen, Jeremy A. , Staffaroni, Adam M. , Taylor, Jack C. , Weıntraub, Sandra , Damme, Philip Van , Van Damme, Philip , Barmada, Sami , Paolillo, Emily W. , Rojas, Julio C. , Miller, Bruce L. , Boeve, Bradley F. , Gendron, Tania F. , Appleby, Brian S. , Botha, Hugo , Bozoki, Andrea C , Clark, David , Coppola, Giovanni, Dickerson, Bradford Clark , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Goldman, Jill , Galasko, Douglas , Huang, Eric J. , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Kantarci, Kejal , Kerwin, Diana , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Pressman, Peter, Ramanan, Vijay K. , Seeley, William W. , Tartaglia, Maria Carmela , VandeVrede, Lawren , Wong, Bonnie

Mayo Clinic

JAMA Neurology | November 14, 2022 | Volume: 80 | Issue: 1 | Pages: 82

10.1001/jamaneurol.2022.4178 | PMID 36374516 Get It

ImportancePhysical activity is associated with cognitive health, even in autosomal dominant forms of dementia. Higher physical activity is associated with slowed cognitive and functional declines over time in adults carrying autosomal dominant variants for frontotemporal lobar degeneration (FTLD), but whether axonal degeneration is a potential neuroprotective target of physical activity in individuals with FTLD is unknown.ObjectiveTo examine the association between physical activity and longitudinal neurofilament light chain (NfL) trajectories in individuals with autosomal dominant forms of FTLD.Design, Setting, and ParticipantsThis cohort study included individuals from the ALLFTD Consortium, which recruited patients from sites in the US and Canada. Symptomatic and asymptomatic adults with pathogenic variants in one of 3 common genes associated with FTLD (GRN, C9orf72, or MAPT) who reported baseline physical activity levels and completed annual blood draws were assessed annually for up to 4 years. Genotype, clinical measures, and blood draws were collected between December 2014 and June 2019; data were analyzed from August 2021 to January 2022. Associations between reported baseline physical activity and longitudinal plasma NfL changes were assessed using generalized linear mixed-effects models adjusting for baseline age, sex, education, functional severity, and motor symptoms.ExposuresBaseline physical activity levels reported via the Physical Activity Scale for the Elderly. To estimate effect sizes, marginal means were calculated at 3 levels of physical activity: 1 SD above the mean represented high physical activity, 0 SD represented average physical activity, and 1 SD below the mean represented low physical activity.Main Outcomes and MeasuresAnnual plasma NfL concentrations were measured with single-molecule array technology.ResultsOf 160 included FTLD variant carriers, 84 (52.5%) were female, and the mean (SD) age was 50.7 (14.7) years. A total of 51 (31.8%) were symptomatic, and 77 carried the C9orf72 variant; 39, GRN variant; and 44, MAPT variant. Higher baseline physical activity was associated with slower NfL trajectories over time. On average, NfL increased 45.8% (95% CI, 22.5 to 73.7) over 4 years in variant carriers. Variant carriers with high physical activity demonstrated 14.0% (95% CI, −22.7 to −4.3) slower NfL increases compared with those with average physical activity and 30% (95% CI, −52.2 to −8.8) slower NfL increases compared with those with low physical activity. Within genotype, C9orf72 and MAPT carriers with high physical activity evidenced 18% to 21% (95% CI, −43.4 to −7.2) attenuation in NfL, while the association between physical activity and NfL trajectory was not statistically significant in GRN carriers. Activities associated with higher cardiorespiratory and cognitive demands (sports, housework, and yardwork) were most strongly correlated with slower NfL trajectories (vs walking and strength training).Conclusions and RelevanceIn this study, higher reported physical activity was associated with slower progression of an axonal degeneration marker in individuals with autosomal dominant FTLD. Physical activity may serve as a primary prevention target in FTLD.
CCRG-02. THE DIFFUSE MIDLINE GLIOMA MUTATIONS, H3.3 K27M AND G34R/V, INHIBIT MITOTIC PHOSPHORYLATION OF SERINE 31, LEADING TO TUMOR FORMATION THROUGH INCREASED CHROMOSOMAL INSTABILITY
Grigore, Florina , Langfald, Alyssa, Hakkim, Faruck Lukmanul , Vaughan, Kevin T. , Hincliffe, Edward, Day, Charles , Daniels, David J. , Robinson, James

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii37-vii38

10.1093/neuonc/noac209.147 Get It

Abstract Diffuse midline gliomas (DMG) are high-grade pediatric gliomas that frequently harbor heterozygous histone H3.3 K27M, G34R, or G34V mutations. These mutations alter histone methylations, although the precise mechanism(s) of gliomagenesis remains uncertain. H3.3 contains a unique Serine at position 31 that is phosphorylated in prophase and dephosphorylated in anaphase during normal cell division. In an aberrant division, chromosome missegregation triggers S31 phosphorylation along chromosome arms in anaphase leading to p53-induced cell cycle arrest. Here we show in vitro and in vivo, that H3.3 K27M, G34R, and G34V significantly suppress S31 phosphorylation by Chk1 (the mitotic S31 kinase). In diploid cells, overexpression of H3.3 K27M, G34R, G34V, or non-phosphorylatable S31A significantly increases the frequency of chromosome missegregation, while H3.3 K36M did not. This missegregation phenotype could be rescued by overexpression of K27M/S31E or G34R/S31E double mutants. Next, we used genome editing to revert K27M or G34V patient-derived DMG cells to WT or replace the mutant allele with S31A. Reversion to WT increased metaphase S31 phosphorylation and reduced chromosome missegregations, but inserting an S31A mutation caused more mitotic defects. Following a mitotic error, newly formed aneuploid cells overexpressing K27M, G34R, or G34V suppress p53 levels and continue to divide, while WT overexpressing cells always arrest. To test the effects of diminished S31 phosphorylation on gliomagenesis, we utilized a novel mouse model of DMG. Expression of PDGFβ linked to H3.3K27M, H3.3G34R, and H3.3S31A in neural stem cells in vivo promoted the development of high-grade gliomas in under 100 days, whereas PDGFβ-H3.3WT did not. Notably, the S31A tumors had histologically normal levels of K27me3 and K36me3. This work shows that a single DMG-associated point mutation in H3.3 can generate chromosomal instability and suggests that chromosomal instability is a major contributing factor to DMG K27-altered and DMG G34-altered tumor formation.
CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT
Polley, Mei‐Yin C. , Shaw, Edward , Buckner, Jan C. , Barger, Geoffrey, Coons, Stephen Joel , Ricci, Peter E. , Gilbert, Mark, Brown, Paul D. , Stelzer, K. , Rogers, Leland , Schultz, Christopher J. , Howard, Steven , Fisher, Barbara, Haddock, Michael G. , Won, Minhee , IWAMOTO, FABIO MASSAITI , Coons, Stephen, Suh, John H. , Kim, Michelle H. , Huang, Jiayi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii73-vii73

10.1093/neuonc/noac209.282 Get It

Abstract BACKGROUND Radiation Therapy Oncology Group 9802 was a phase III trial for patients with centrally confirmed LGG (WHO grade II). Participants ³ 40 years or those with neurosurgeon defined less than gross total resection (GTR) were randomized to radiotherapy (RT) +/- PCV. In a separate cohort, adults age < 40 years with neurosurgeon defined GTR were observed by MRI every 6 months without adjuvant therapy. At last report, outcome for the observation cohort was immature with median follow-up of only 4.4 years. Here, we present mature outcomes for the observation arm. METHODS Eligible adults (as above) were observed by MRI every 6 months. OS and PFS were estimated by Kaplan-Meier method and estimated hazard ratios to characterize the prognostic variables. RESULTS There were 111 eligible patients (median age 30; median KPS = 100). Median follow-up was 16.1 years with 71 (64%) alive at the last follow-up. 79 patients (71%) had progressed with median PFS of 6.9 years. 5, 10, and 15 year-PFS and OS rates were 54%, 39%, 28% and 94%, 77%, and 65%. 1p19q status was codeleted in 32%, IDH1/2 mutant in 78% and MGMT promoter methylated in 39% of tested cases. Multivariate Cox analyses showed that preoperative tumor size ³ 4 cm (HR = 2.43 for PFS, p = 0.001; HR = 2.58 for death, p = 0.016) and residual disease on imaging ³ 1 cm (HR = 2.97 for PFS, P < 0.001; HR = 2.02 for death, p = 0.05) were associated with worse outcomes. Analyses based on molecular results will be presented. CONCLUSION A subset of low-grade gliomas can be observed after the initial resection based on younger age, smaller tumor size, and no residual disease on neuroimaging. This can likely be further refined by prognostic molecular markers. Patients with the most favorable prognostic factors can avoid or delay the acute and long-term side effects of RT and chemotherapy for several years.
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Mehren, Margaret von , Riedel, Richard F. , Agulnik, Mark , Carr, Janai R. , Connelly, Mary, Ganjoo, Kristen N. , Holder, Ashley M. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Mesko, Nathan W. , Meyer, Christian F. , Pappo, Alberto S. , Petersen, Ivy A. , Poppe, Matthew M. , Schuetze, Scott M. , Shabason, Jacob E. , Zimel, Melissa N. , Bergman, Mary Anne, Sundar, Hema, Hang, Lisa E., Riedel, Richard F , von Mehren, Margaret , Kane, John M., Sicklick, Jason Keith , Pollack, Seth M. , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , González, Ricardo , Liebner, David A. , Parkes, Amanda , Spraker, Matthew B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 9, 2022 | Volume: 20 | Issue: 11 | Pages: 1204-1214

10.6004/jnccn.2022.0058 | PMID 36351335 Get It

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.
666 Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
Uchio, Edward , Lamm, Donald L. , Paras, Shah, Bivalacqua, Trinity J. , McAdory, John, Hnat, Nataliya, Burke, James , Li, Roger , Steinberg, Gary K. , Kamat, Ashish M. , Packiam, Vignesh T. , Chisamore, Michael Jon , Grandi, Paola

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A696-A696

10.1136/jitc-2022-sitc2022.0666 Get It

639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy
Morelli, Maria Pia , Hecht, J. Randolph, Patel, Sandip Pravin , Welling, Theodore H., Larson, Sarah , Kato, Shumei , Vu, Peter , Sunwoo, John B. , Miklos, David B. , Nikiforow, Sarah , Jacobson, Caron A. , Liechty, Kirstin B., Mardiros, Armen, Lozac’hmeur, Ariane, Beutner, Karl R., Welch, John S. , Go, William Y., Maloney, David G. , Molina, Julian R. , Miklos, David B , Simeone, Diane M. , Fakih, Marwan , Kirtane, Kedar , Lau, Sally C. M. , Lin, Yi , Borad, Mitesh J. , Garon, Edward B. , Locke, Frederick L. , Kim, Dae Won , Frigault, Matthew J. , Maus, Marcela V , Ng, Eric, Kopetz, Scott

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A670-A670

10.1136/jitc-2022-sitc2022.0639 Get It

437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium
Zarif, Talal El , Adib, Elio , Fitzgerald, Bailey G. , Huang, Jiaming , Nonato, Taylor K., McKay, Rana R. , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazlı , Emu, Brinda , Falohun, Adewunmi, Abdel‐Wahab, Noha , Bankapur, Anand, Reed, Alexandra, Kim, Chul , Arora, Aakriti, Shah, Neil P. , El‐Am, Edward , Abdallah, Wassim , Al‐Hader, Ahmad, Ghazal, Batool Abu, Drolen, Claire , Espinar, Javier Baena , Nebhan, Caroline A. , Haykal, Tarek , Morse, Michael A. , Pria, Alessia Dalla , Bower, Mark , Bakalov, Veli , Bahary, Nathan , Rajkumar, Aarthi , Shah, Vishal , Lopetegui‐Lia, Nerea , AO, Georgina Long, Genova, Carlo , Barletta, Giulia, Idossa, Damé , Lamberti, Giuseppe , Freeman, Dory , Baden, Lindsey R. , Sonpavde, Guru , Naqash, Abdul Rafeh , Shah, Vishal , Genova, Carlo , Bower, Mark , Naqash, Abdul Rafeh , Nassar, Amin H. , Mouhieddine, Tarek H. , Li, Mingjia , Mittra, Arjun , Owen, Dwight H , Dobbs, Ryan W. , Shah, Neil, Kozaily, Elie , Saeed, Anwaar , Lechner, Melissa G , Johnson, Douglas, Cortellini, Alessio , Pinato, David J. , Hall, Evan, Mangla, Ankit , Singh, Parminder , Nana, Frank Aboubakar , Dima, Danai , Funchain, Pauline , Saleem, Rabia, Woodford, Rachel , Menzies, Alexander M , Puri, Sonam , Florou, Vaia , Queirolo, Paola , Addeo, Alfredo , Bersanelli, Melissa , Xie, Wanling , Ramaswami, Ramya , Marron, Thomas , Choueiri, Toni K. , Lurain, Kathryn

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A457-A458

10.1136/jitc-2022-sitc2022.0437 Get It

229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer
Hecht, J. Randolph, Sandberg, Mark, Wang, Xueyin , Martin, Aaron, Nampe, Daniel , Gabrelow, Grant B. , Li, Chuck, McElvain, Michele , Lee, Wen-Hua , Shafaattalab, Sanam , Martire, Sara , Fisher, F. , Ando, Yuta, Liu, Edwin , Ju, David, Hsin, Jing-Ping, Zampieri, Alexandre, Morelli, Maria Pia , Welling, Theodore H., Patel, Sandip Pravin , Welch, John S. , Go, William Y., Mardiros, Armen, Maloney, David G. , Wong, Lu-Min, Xu, Han , Molina, Julian R. , Ando, Yuta, Liu, Edwin, Ju, David, Simeone, Diane M. , Kopetz, Scott , Borad, Mitesh J. , Garon, Edward B. , Kirtane, Kedar , Locke, Frederick L. , Ng, Eric, Kamb, Alexander

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A242-A242

10.1136/jitc-2022-sitc2022.0229 Get It